Quantcast
Last updated on April 18, 2014 at 16:41 EDT

Latest Head and neck cancer Stories

2012-05-16 14:22:22

RIDGEFIELD, Conn., May 16, 2012 /PRNewswire/ -- Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012. LUX-Lung 3, which compares the investigational oral, once-daily...

2012-05-15 12:44:25

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily. The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal...

2012-05-14 02:25:12

-Two-time Oscar Winner and Cancer Survivor Encourages Regular Screenings as Counter to Rising Incidence Rates of Oral Cancer- LOS ANGELES, May 14, 2012 /PRNewswire-USNewswire/ -- Actor and producer Michael Douglas has donated his time to help create a television public service announcement (PSA) on behalf of the Oral Cancer Foundation (OCF), a non-profit organization dedicated to helping those affected by the disease. The PSA will support the Foundation's efforts to educate the...

2012-05-11 14:23:09

Results from a randomized trial in head and neck cancer Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumor and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can be overcome by the use of a treatment known as ARCON therapy, in which accelerated radiotherapy is combined with carbogen (a mixture of carbon...

2012-05-10 09:42:25

New findings from a large Danish database of cancer patients suggest that, even though the human papilloma virus (HPV) can trigger throat cancer, patients who are HPV-positive and are light smokers, or don't smoke at all, have a good response to treatment using radiotherapy alone, without the addition of chemotherapy with its consequent toxic side-effects. Presenting her research at the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) [1] today [Thursday],...

2012-05-10 09:27:31

Researchers believe they may have found a way to avoid damaging salivary glands during radiotherapy treatment for head and neck cancer — a discovery that could improve the quality of life of 500,000 patients a year worldwide with the disease. Presenting their findings to the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO31) [1], the researchers said that they had discovered that the stem cells essential for regenerating the parotid gland (the largest...

2012-05-03 02:31:45

CALGARY, May 3, 2012 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN(®) in patients with advanced or metastatic colorectal cancer. "We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and...

2012-05-02 02:26:47

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV) announced today that the Company has initiated development of a diagnostic test to determine the presence of high risk Human Papilloma Virus (HPV) subtypes from urine specimens. The proprietary test (U.S. patent application pending) might, once available, be particularly useful for the determination of carrier status in males. The Company's HPV detection assay is a unique, proprietary(1) method that preferentially...

2012-04-27 00:05:50

Researchers at The Wistar Institute announce the discovery of small molecules that kill cancer cells caused by infection with human papillomavirus (HPV).  Their results, in both cell and mouse models, demonstrate that the small molecule inhibitors protect a tumor-suppressing protein targeted by viral proteins, thus killing the infected tumor cells. The Wistar scientists presented their findings in the April 20 issue of the journal Chemistry & Biology.  The researchers believe...

2012-04-26 06:25:55

OKEMOS, Mich., April 26, 2012 /PRNewswire/ -- New research coming out of Delta Dental of Michigan's Research and Data Institute (RDI) finds that in the United States, the cost of oral cavity (OC), oral pharyngeal (OP), and salivary gland (SG) cancer may be the most costly cancer in the nation to treat. Details of the study will be published in BioMed Central's open access journal Head and Neck Oncology today. The project, which involved key partners including Thomson Reuters, Delta Dental of...